BRISTOL-MYERS SQUIBB CO (1BMY.MI) Stock Fundamental Analysis
BIT:1BMY - Euronext Milan - US1101221083 - Common Stock - Currency: EUR
1BMY gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 52 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of 1BMY get a neutral evaluation. Nothing too spectacular is happening here. 1BMY is valued quite cheap, while showing a decent growth score. This is a good combination! 1BMY also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
In the past year 1BMY was profitable.
In the past year 1BMY had a positive cash flow from operations.
In multiple years 1BMY reported negative net income over the last 5 years.
1BMY had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
1BMY has a Return On Assets of 5.86%. This is comparable to the rest of the industry: 1BMY outperforms 56.60% of its industry peers.
1BMY's Return On Equity of 31.16% is fine compared to the rest of the industry. 1BMY outperforms 77.36% of its industry peers.
1BMY has a better Return On Invested Capital (14.13%) than 77.36% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for 1BMY is below the industry average of 14.50%.
The 3 year average ROIC (11.67%) for 1BMY is below the current ROIC(14.13%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.86% | ||
| ROE | 31.16% | ||
| ROIC | 14.13% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)11.67%
ROIC(5y)9.83%
1.3 Margins
The Profit Margin of 1BMY (11.38%) is comparable to the rest of the industry.
The Operating Margin of 1BMY (27.11%) is better than 73.58% of its industry peers.
In the last couple of years the Operating Margin of 1BMY has declined.
1BMY has a Gross Margin of 74.69%. This is in the better half of the industry: 1BMY outperforms 67.92% of its industry peers.
1BMY's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.11% | ||
| PM (TTM) | 11.38% | ||
| GM | 74.69% |
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), 1BMY is creating some value.
The number of shares outstanding for 1BMY has been reduced compared to 1 year ago.
The number of shares outstanding for 1BMY has been reduced compared to 5 years ago.
The debt/assets ratio for 1BMY is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 2.08 indicates that 1BMY is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of 1BMY (2.08) is worse than 62.26% of its industry peers.
1BMY has a debt to FCF ratio of 3.80. This is a good value and a sign of high solvency as 1BMY would need 3.80 years to pay back of all of its debts.
1BMY's Debt to FCF ratio of 3.80 is in line compared to the rest of the industry. 1BMY outperforms 56.60% of its industry peers.
A Debt/Equity ratio of 2.67 is on the high side and indicates that 1BMY has dependencies on debt financing.
With a Debt to Equity ratio value of 2.67, 1BMY is not doing good in the industry: 79.25% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.67 | ||
| Debt/FCF | 3.8 | ||
| Altman-Z | 2.08 |
ROIC/WACC1.56
WACC9.08%
2.3 Liquidity
1BMY has a Current Ratio of 1.28. This is a normal value and indicates that 1BMY is financially healthy and should not expect problems in meeting its short term obligations.
1BMY's Current ratio of 1.28 is on the low side compared to the rest of the industry. 1BMY is outperformed by 60.38% of its industry peers.
A Quick Ratio of 1.17 indicates that 1BMY should not have too much problems paying its short term obligations.
1BMY's Quick ratio of 1.17 is fine compared to the rest of the industry. 1BMY outperforms 73.58% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.28 | ||
| Quick Ratio | 1.17 |
3. Growth
3.1 Past
1BMY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 599.05%, which is quite impressive.
1BMY shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -24.57% yearly.
1BMY shows a small growth in Revenue. In the last year, the Revenue has grown by 4.62%.
1BMY shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.06% yearly.
EPS 1Y (TTM)599.05%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%140.91%
Revenue 1Y (TTM)4.62%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%-5.6%
3.2 Future
Based on estimates for the next years, 1BMY will show a very strong growth in Earnings Per Share. The EPS will grow by 37.10% on average per year.
Based on estimates for the next years, 1BMY will show a decrease in Revenue. The Revenue will decrease by -4.93% on average per year.
EPS Next Y509.67%
EPS Next 2Y133.09%
EPS Next 3Y74.89%
EPS Next 5Y37.1%
Revenue Next Year-3.36%
Revenue Next 2Y-5.2%
Revenue Next 3Y-3.73%
Revenue Next 5Y-4.93%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 6.50, the valuation of 1BMY can be described as very cheap.
Compared to the rest of the industry, the Price/Earnings ratio of 1BMY indicates a rather cheap valuation: 1BMY is cheaper than 92.45% of the companies listed in the same industry.
1BMY is valuated cheaply when we compare the Price/Earnings ratio to 27.30, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 7.71, the valuation of 1BMY can be described as very cheap.
Based on the Price/Forward Earnings ratio, 1BMY is valued cheaper than 94.34% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.76, 1BMY is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.5 | ||
| Fwd PE | 7.71 |
4.2 Price Multiples
1BMY's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. 1BMY is cheaper than 86.79% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, 1BMY is valued cheaper than 94.34% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.43 | ||
| EV/EBITDA | 6.38 |
4.3 Compensation for Growth
1BMY's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
1BMY's earnings are expected to grow with 74.89% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y133.09%
EPS Next 3Y74.89%
5. Dividend
5.1 Amount
1BMY has a Yearly Dividend Yield of 4.89%, which is a nice return.
1BMY's Dividend Yield is rather good when compared to the industry average which is at 3.00. 1BMY pays more dividend than 86.79% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.35, 1BMY pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.89% |
5.2 History
On average, the dividend of 1BMY grows each year by 11.67%, which is quite nice.
Dividend Growth(5Y)11.67%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
1BMY pays out 90.59% of its income as dividend. This is not a sustainable payout ratio.
1BMY's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP90.59%
EPS Next 2Y133.09%
EPS Next 3Y74.89%
BIT:1BMY (5/27/2025, 7:00:00 PM)
41.495
+0.26 (+0.63%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners82.11%
Inst Owner ChangeN/A
Ins Owners0.03%
Ins Owner ChangeN/A
Market Cap84.45B
Analysts67.5
Price Target49.08 (18.28%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.89% |
Yearly Dividend2.1
Dividend Growth(5Y)11.67%
DP90.59%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.45%
Min EPS beat(2)13.54%
Max EPS beat(2)19.36%
EPS beat(4)4
Avg EPS beat(4)19.59%
Min EPS beat(4)13.54%
Max EPS beat(4)25.96%
EPS beat(8)7
Avg EPS beat(8)11.3%
EPS beat(12)11
Avg EPS beat(12)9.38%
EPS beat(16)15
Avg EPS beat(16)7.79%
Revenue beat(2)2
Avg Revenue beat(2)4.66%
Min Revenue beat(2)3.68%
Max Revenue beat(2)5.63%
Revenue beat(4)4
Avg Revenue beat(4)4.59%
Min Revenue beat(4)3.68%
Max Revenue beat(4)5.63%
Revenue beat(8)6
Avg Revenue beat(8)1.95%
Revenue beat(12)8
Avg Revenue beat(12)1.4%
Revenue beat(16)10
Avg Revenue beat(16)1.19%
PT rev (1m)-11.93%
PT rev (3m)-12.22%
EPS NQ rev (1m)-2.94%
EPS NQ rev (3m)-4.8%
EPS NY rev (1m)0%
EPS NY rev (3m)1.94%
Revenue NQ rev (1m)-0.01%
Revenue NQ rev (3m)-0.04%
Revenue NY rev (1m)-0.04%
Revenue NY rev (3m)1.33%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.5 | ||
| Fwd PE | 7.71 | ||
| P/S | 2.04 | ||
| P/FCF | 7.43 | ||
| P/OCF | 6.79 | ||
| P/B | 5.59 | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.38 |
EPS(TTM)6.38
EY15.38%
EPS(NY)5.38
Fwd EY12.97%
FCF(TTM)5.59
FCFY13.46%
OCF(TTM)6.11
OCFY14.72%
SpS20.33
BVpS7.42
TBVpS-11.45
PEG (NY)0.01
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.86% | ||
| ROE | 31.16% | ||
| ROCE | 18.89% | ||
| ROIC | 14.13% | ||
| ROICexc | 17.06% | ||
| ROICexgc | 77.14% | ||
| OM | 27.11% | ||
| PM (TTM) | 11.38% | ||
| GM | 74.69% | ||
| FCFM | 27.47% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)11.67%
ROIC(5y)9.83%
ROICexc(3y)13.73%
ROICexc(5y)11.7%
ROICexgc(3y)74.94%
ROICexgc(5y)75.96%
ROCE(3y)15.62%
ROCE(5y)13.15%
ROICexcg growth 3Y-15.94%
ROICexcg growth 5Y3.18%
ROICexc growth 3Y7.54%
ROICexc growth 5Y19.82%
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
F-Score7
Asset Turnover0.52
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.67 | ||
| Debt/FCF | 3.8 | ||
| Debt/EBITDA | 2.21 | ||
| Cap/Depr | 15.15% | ||
| Cap/Sales | 2.57% | ||
| Interest Coverage | 6.1 | ||
| Cash Conversion | 68.16% | ||
| Profit Quality | 241.48% | ||
| Current Ratio | 1.28 | ||
| Quick Ratio | 1.17 | ||
| Altman-Z | 2.08 |
F-Score7
WACC9.08%
ROIC/WACC1.56
Cap/Depr(3y)12.09%
Cap/Depr(5y)10.53%
Cap/Sales(3y)2.56%
Cap/Sales(5y)2.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)599.05%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%140.91%
EPS Next Y509.67%
EPS Next 2Y133.09%
EPS Next 3Y74.89%
EPS Next 5Y37.1%
Revenue 1Y (TTM)4.62%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%-5.6%
Revenue Next Year-3.36%
Revenue Next 2Y-5.2%
Revenue Next 3Y-3.73%
Revenue Next 5Y-4.93%
EBIT growth 1Y22.52%
EBIT growth 3Y0.79%
EBIT growth 5Y8.21%
EBIT Next Year282.44%
EBIT Next 3Y50.39%
EBIT Next 5Y24.24%
FCF growth 1Y18.09%
FCF growth 3Y-2.91%
FCF growth 5Y14.03%
OCF growth 1Y17.06%
OCF growth 3Y-2.14%
OCF growth 5Y13.49%